US equities
|
GOOGL
$281.42
▼-13.38%
GOOG
$279.38
▼-13.20%
MSFT
$529.25
▼-0.33%
META
$626.17
▲+2.23%
MU
$932.39
▼-5.17%
NVDA
$212.88
▼-1.16%
AMZN
$244.69
▼-3.89%
AAPL
$349.91
▲+1.77%
GOOGL
$281.42
▼-13.38%
GOOG
$279.38
▼-13.20%
MSFT
$529.25
▼-0.33%
META
$626.17
▲+2.23%
MU
$932.39
▼-5.17%
NVDA
$212.88
▼-1.16%
AMZN
$244.69
▼-3.89%
AAPL
$349.91
▲+1.77%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
ACADIA Pharmaceuticals Inc. - Common Stock
(NQ:
ACAD
)
20.54
+0.22 (+1.08%)
Delayed Quote
Updated: 2:25 PM EDT, Oct 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about ACADIA Pharmaceuticals Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis Trial
↗
September 24, 2026
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported top-line results from the phase II portion of its RADIANT clinical program evaluating remlifanserin for hallucinations and delusions associated with...
Via
MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Displays High Growth Momentum and a Breakout Setup
↗
August 31, 2026
Via
Chartmill
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data
↗
August 12, 2026
ACADIA Pharmaceuticals (NASDAQ:ACAD) outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer’s...
Via
MarketBeat
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript
↗
August 11, 2026
Revenue hit $308 million with 17% growth, driven by DAYBUE and NUPLAZID demand.
Via
The Motley Fool
Topics
Earnings
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 Earnings Beat, Stock Rises on Raised Guidance
↗
August 04, 2026
Via
Chartmill
Topics
Earnings
Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower
↗
May 06, 2026
Via
Chartmill
Topics
Earnings
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Surpasses $1 Billion Revenue Milestone in 2025, Beats Q4 EPS Estimates
↗
February 25, 2026
Via
Chartmill
ACADIA Pharmaceuticals Q2 Earnings Call Highlights
↗
August 04, 2026
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported second-quarter 2026 revenue of $308 million, representing 17% year-over-year growth on an adjusted basis, as sales of its Rett syndrome therapy DAYBUE and...
Via
MarketBeat
Topics
Earnings
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
↗
July 11, 2026
Acadia Pharmaceuticals specializes in CNS therapies; a key insider recently trimmed their stake amid ongoing product pipeline developments.
Via
The Motley Fool
Topics
Regulatory Compliance
Why Acadia Pharmaceuticals Stock Is Soaring Today
↗
June 26, 2026
An approval of one of its drugs for a major market is now looking likely.
Via
The Motley Fool
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Emerges as a Value Stock with Strong Fundamentals
↗
February 06, 2026
Via
Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup
↗
January 16, 2026
Via
Chartmill
Traders are paying attention to the gapping stocks in Friday's session.
↗
June 26, 2026
Via
Chartmill
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
↗
June 26, 2026
Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc...
Via
Benzinga
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth
↗
May 19, 2026
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide...
Via
MarketBeat
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
↗
May 12, 2026
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders,...
Via
MarketBeat
Acadia (ACAD) Q1 2026 Earnings Transcript
↗
May 06, 2026
Acadia (ACAD) Q1 2026 Earnings Transcript
Via
The Motley Fool
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
April 07, 2026
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive...
Via
MarketMinute
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
April 07, 2026
The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most...
Via
Finterra
Topics
Economy
Intellectual Property
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
April 06, 2026
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has...
Via
MarketMinute
Topics
Intellectual Property
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
↗
March 03, 2026
PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
↗
March 02, 2026
This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
↗
March 02, 2026
This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets.
Via
The Motley Fool
Topics
Regulatory Compliance
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts
↗
February 27, 2026
The company said that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study.
Via
Stocktwits
ACADIA (ACAD) Q4 2025 Earnings Call Transcript
↗
February 25, 2026
ACADIA (ACAD) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
↗
February 23, 2026
Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50%
↗
February 23, 2026
GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.
Via
The Motley Fool
Topics
Regulatory Compliance
ACAD Stock Slumps 8% After Hours On Hurdle To EU Approval For Genetic Disorder Drug
↗
February 02, 2026
The company said that the Committee for Medicinal Products for Human Use informed it of a negative trend around its application after an oral explanation recently.
Via
Stocktwits
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
December 30, 2025
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...
Via
MarketMinute
Topics
ETFs
Economy
World Trade
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup for Breakout
↗
December 25, 2025
ACADIA Pharmaceuticals shows strong earnings momentum and a bullish technical setup, presenting a potential breakout opportunity for growth investors.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
